| Clinical improvement |
| BSA (%) | 37.9±16.3 | 3.1±5.5 | <0.001 |
| PASI (0–72) | 18.9±7.8 | 1.3±2.1 | <0.001 |
| NAPSI hands (0–80) | 5.4±10.5 | 1.5±3.9 | 0.26 |
| PGA psoriasis (0–6) | 3.9±0.6 | 0.7±0.6 | <0.001 |
| PASE total score (15–75) | 32.5±15.9 | 25.2±13.0 | 0.007 |
| PASE (functional) (8–40) | 15.9±8.7 | 12.1±6.2 | 0.013 |
| PASE symptoms (7–35) | 16.6±7.7 | 13.1±7.3 | 0.014 |
| BASDAI | 2.61±2.77 | 1.26±1.31 | 0.11 |
| BASFI | 1.31±1.97 | 0.82±1.62 | 0.29 |
| Patients with arthritis | 26,1% | 15,0% | 0.004 |
| Histological improvement in simple with psoriasis |
| VEGF (% positive) | 86,9% | 17,4% | <0.001 |
| VEGF (% negative) | 13,1% | 82,6% | <0.001 |
| TNFα (% positive) | 82,6% | 8,6% | <0.001 |
| TNFα (% negative) | 17,4% | 8,6% | <0.001 |
| CD31 (median [IQR]) | 2117 [843–1590] | 987 [684–1590] | <0.001 |